期刊
CURRENT TOPICS IN MEDICINAL CHEMISTRY
卷 14, 期 3, 页码 319-325出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568026613666131126224039
关键词
Caspacse-6; alzheimer's disease; huntington's disease; zymogen; intellectual property; exclusively; high throughput screening; tethering
Partnerships between industry and academia are becoming increasingly complex and relevant in the drive to discover innovative new medicines. We describe the structure of the collaboration between the University of California - San Francisco - Small Molecule Discovery Center (UCSF-SMDC) and Genentech to develop chemical matter that inhibits the activity of caspase-6. We focus on the scientific basis for the partnership and how the orientation-and transaction-related barriers were overcome. We describe the division of labor that allowed two groups to operate as a unified team to generate multiple chemical series with distinct mechanisms of action. The successful structure of the agreement serves as a model for future collaborations at both institutions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据